Nov 12, 2020
American Regent, Inc. Announces CEO Transition for 2021
Jun 15, 2020
American Regent Inc Selects Sparta Systems' TrackWise Digital QMS to Seamlessly Connect Quality Across Manufacturing, Clinical and Supplier Network
May 11, 2020
American Regent Introduces niCARdipine Hydrochloride Injection, USP­; AP Rated and Therapeutically Equivalent to Cardene® (1, 2)
Mar 04, 2020
Gastric Cancer Drugs Industry Forecast to 2030 - Landscape Dominated by Eli Lilly & Company, Novartis, Merck, Otsuka Pharma, and Roche
Jan 08, 2020
Immunic Exercises its Option for the Exclusive Worldwide License to IMU-856 from Daiichi Sankyo Co., Ltd.
Nov 12, 2019
Sosei Heptares Operational Highlights and Consolidated Results for the Nine Months Ended 30 September, 2019
Nov 04, 2019
Daiichi Sankyo Files Declaratory Judgement Action Related to its Proprietary Antibody Drug Conjugate Technology
Nov 03, 2019
AstraZeneca Tops the First Pharmaceutical Invention Index
Sep 10, 2019
Updated Clinical Results and New Biomarker Analyses Presented for Daiichi Sankyo's DS-1062 in Patients with Advanced NSCLC at 2019 World Conference on Lung Cancer
Sep 10, 2019
Updated Phase 1 Data for Daiichi Sankyo's U3-1402 in Patients with EGFR Mutated NSCLC Presented at 2019 World Conference on Lung Cancer
Sep 06, 2019
Visiongain Report Analyses Leading Players within the $1.4bn Pharmaceutical Wholesale & Distribution Market
Aug 21, 2019
Updated Clinical Results and New Translational Research Data for Daiichi Sankyo's ADCs U3-1402 and DS-1062 to be Presented at the 2019 World Conference on Lung Cancer
Aug 12, 2019
Daiichi Sankyo, Inc. Appoints Simon King as Chief People Officer across U.S. Divisions
Aug 02, 2019
FDA Approves Daiichi Sankyo's TURALIO(TM) (pexidartinib) for the Treatment of Select Patients with TGCT, a Rare and Debilitating Tumor
Jul 10, 2019
American Regent Announces the Launch and Availability of Selenious Acid Injection, USP­
Jun 02, 2019
Daiichi Sankyo Presents Preliminary Phase 1 Data for TROP2 Targeting ADC DS-1062 in Patients with Non-Small Cell Lung Cancer at 2019 ASCO Annual Meeting
Jun 01, 2019
Daiichi Sankyo's Pexidartinib Demonstrated Further Improvement with Continued Treatment of Tenosynovial Giant Cell Tumor Patients in New Long-Term Analysis Presented at 2019 ASCO Annual Meeting
May 31, 2019
Daiichi Sankyo Presents Preliminary Phase 1 Data for HER3 Targeting ADC U3-1402 in Patients with EGFR Mutated Non-Small Cell Lung Cancer at 2019 ASCO Annual Meeting
May 28, 2019
Integral Molecular Reaches Milestone in Immuno-Oncology Target Discovery Collaboration with Daiichi Sankyo
May 15, 2019
Daiichi Sankyo Data Presentations at 2019 ASCO Annual Meeting Highlight Depth of ADC Pipeline and Promises of Oncology Portfolio